生命科学资讯

Assessing 10x Genomics (TXG) Valuation After Recent Share Price Momentum - simplywall.st

10x Genomics Earnings Call: Consumables Shine, CapEx Bites - TipRanks

Lonza’s Stock In Recovery Mode: Is This Swiss CDMO Finally Back On Track? - AD HOC NEWS

Lonza’s Stock In Recovery Mode: Is This Swiss CDMO Finally Back On Track? - AD HOC NEWS

The Bull Case For Agilent Technologies (A) Could Change Following New PD-L1 Test Approval And Dividend News - simplywall.st

Moderna vs FDA; Paul Hudson out at Sanofi; Why clinical trials are so costly; and more

Agilent Technologies, Inc. $A Shares Sold by ING Groep NV - MarketBeat

Thermo Fisher Scientific (TMO) Announces $3.8 Billion Senior Not - GuruFocus

Assetmark Inc. Boosts Position in Agilent Technologies, Inc. $A - MarketBeat

Illumina (NASDAQ:ILMN) Upgraded by Wall Street Zen to Strong-Buy Rating - MarketBeat

Risk Factors Weigh on 10X Genomics: Uncertain Guidance, Stock Volatility, and Capital-Raising Challenges - TipRanks

Decoding 10x Genomics Inc (TXG): A Strategic SWOT Insight - GuruFocus

Shrinking TTM Loss At 10x Genomics (TXG) Tests Bearish Earnings Narratives - simplywall.st

Shrinking TTM Loss At 10x Genomics (TXG) Tests Bearish Earnings Narratives - simplywall.st

'It's really a dire time for patients': Biohaven CEO says FDA red tape is blocking access to rare disease treatments

FDA rejects Disc's rare disease drug despite commissioner's voucher

From sample to insight: Streamlining analysis with the Illumina 5-base solution - Illumina

Illumina completes acquisition of SomaLogic from Standard BioTools - BizWest

Expert Outlook: 10x Genomics Through The Eyes Of 10 Analysts - Benzinga

With the FDA's Moderna decision, vaccine makers face increasingly uncertain regulatory environment